A phase 3 trial of Gilead Sciences’ remdesivir has demonstrated positive results in patients with moderate COVID-19 symptoms.

The study evaluated five-day and 10-day courses of the investigational antiviral plus the standard of care vs. standard of care alone.

Patients given remdesivir for five days were 65 percent more likely to have clinical improvement at day 11 compared with those in the standard of care group. The improvement in the patients given the 10-day treatment was not significantly better than in the five-day group.